'김갑성' 기자의 전체기사
-
Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (am…
Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more than one year First and only chemotherapy-free combination in the first line setting to show survival improvement of this magnitude in a population with the highest-prevalence of EGFR-mutated lung cancer SINGAPORE, Sept. 12, 2025 -- Johnson & Johnson today announced positive topline results for overall survival (OS) from the Asia cohort of the Phase 3 MARIPOSA study, evaluating amivantamab plus lazertinib as a first-
- 김갑성 기자
- 2025-09-12 11:00
-
Smartee and Shanghai Ninth People's Hospital Win First Prize…
SHANGHAI, Sept. 12, 2025 -- Smartee Denti-Technology, a global innovator in invisible orthodontic solutions, together with Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, has been awarded the First Prize of the Shanghai Science and Technology Progress Award. This prestigious recognition highlights the two institutions' joint achievements in advancing precision surgery for complex craniofacial deformities. Award and Background: The Shanghai Science and Technology Progress Award, established by the Shanghai Municipal People's Gove
- 김갑성 기자
- 2025-09-12 10:03
-
The New Drug Application for KN026 (Anbenitamab Injection) H…
SUZHOU, China, Sept. 12, 2025 -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been accepted by the National Medical Products Administration (NMPA). KN026 has been applied for as a Class 1 therapeutic biological product and the indication is for use in combination with chemotherapy for the treatment of patients with HER2-positive locally a
- 김갑성 기자
- 2025-09-12 09:51
-
Psoriatic Disease To Take Center Stage at the UN General As…
STOCKHOLM, Sept. 12, 2025 -- The International Federation of Psoriasis Associations (IFPA) spotlights psoriatic disease at the upcoming UNGA 80 in New York, where world leaders are expected to adopt a new Political Declaration on noncommunicable diseases (NCDs), mental health and well-being. Key Highlights: An estimated 60 million people worldwide are affected by psoriatic disease - a serious, lifelong noncommunicable disease that impacts the skin, joints, and other organs. Psoriasis also increases risks for diabetes, obesity, cardiovascular disease and depres
- 김갑성 기자
- 2025-09-12 00:16
-
Zhimeng Biopharma's Investigational Drug Approved to Initiat…
SHANGHAI, Sept. 12, 2025 -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a Phase 2 clinical trial in China for refractory epilepsy. This follows the CDE's approval in July of this year for Phase 2/3 clinical studies in amyotrophic lateral sclerosis (ALS). The upcoming trial is a randomized, double-blind, placebo-contro
- 김갑성 기자
- 2025-09-12 00:00
-
Datasea Secures Landmark Agreement for First Acoustic Wea…
Driving the Commercialization of Acoustic Technology in Smart Health Wearables through Solution-Based Service Delivery BEIJING, Sept. 11, 2025 -- Datasea Inc. (NASDAQ: DTSS), a Nevada-based technology company specializing in acoustic high-tech products and AI multimodal digital solutions, today announced that its VIE entity in China, Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd., has signed a service agreement with Hainan Zhixingjian Intelligent Technology Co., Ltd.( "Hainan Zhixingjian"). The two companies will collaborate on the commercialization of aco
- 김갑성 기자
- 2025-09-11 21:30
-
GLOBAL FIRST "High-Definition Image": Decoding the "Code of…
CHENGDU, China, Sept. 11, 2025 -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achieved high-resolution, molecular-level visualization of "collagen fiber bundles" under near-physiological and ultra-low temperature conditions using Cryo-Electron Microscopy (Cryo-EM). This achievement fills an international gap in the structural understanding of collagen fiber self-assembly
- 김갑성 기자
- 2025-09-11 21:27
-
Lunit Awarded Major National Tender in France, Expanding…
Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its breast imaging AI solutions have been selected under a national framework agreement led by UniHA, the largest central public procurement body for French hospitals. Under this four-year agreement, Lunit INSIGHT® MMG and DBT—Lunit's AI-powered software for mammography
- 김갑성 기자
- 2025-09-11 21:00
-
Strider Technologies、NATOの防衛イノベーション・アクセラレーターとの…
NATO DIANAは、Striderの戦略的情報を経済安全保障ツールとして活用 ロンドン, 2025年9月11日 -- 戦略インテリジェンスの大手プロバイダーであるStrider Technologies, Inc.は本日、NATOの北大西洋防衛イノベーション・アクセラレーター（Defence Innovation Accelerator for the North Atlantic、DIANA）との新たなパートナーシップを発表しました。 このパートナーシップに基づき、Striderは経済安全保障機能を提供し、NATO 2022戦略コンセプト（NATO 2022 Strategic Concept）に定められた戦略的競争相手からの契約およびサプライ・チェーンのリスクを特定するためにNATO DIANAを支援します。 Striderの戦略的インテリジェンスは、DIANA防衛イノベーション・エコシステムに参加して協力したい組織や個人からのリスクを評価するためにも使用されます。 「NATOの北大西洋防衛イノベーション・アクセラレーター（Defence Innovation Accelerator for the North Atlantic）は、同盟の安全保障に不可欠な貢献をするイノベーター、起業家、メンターのダイナミックなエコシステムを構
- 김갑성 기자
- 2025-09-11 20:36
-
GLOBAL FIRST "High-Definition Image": Decoding the "Code of…
CHENGDU, China, Sept. 11, 2025 -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of "collagen fiber bundles" using Cryo-Electron microscopy (Cryo-EM) under near-physiological and cryogenic conditions. This breakthrough fills the international knowledge gap in understanding collagen's self-assembly mechanism. The result was achieved through collaboration with the Cryo-EM platform te
- 김갑성 기자
- 2025-09-11 20:26
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
- 제2회 마나르 아부다비 출품 작가 명단 공개 00:48
- 중국-피지 어업 협력, 섬나라 경제 활력 끌어올리다 00:00
2025-10-18_SAT
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 19일 16시 40분